The male infertility market size has grown strongly in recent years. It will grow from $4.33 billion in 2025 to $4.57 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to declining sperm quality globally, increased prevalence of lifestyle-related infertility, expansion of fertility clinics, growing acceptance of art procedures, advancements in semen analysis techniques.
The male infertility market size is expected to see strong growth in the next few years. It will grow to $5.76 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to rising infertility rates due to environmental factors, increasing demand for ivf and icsi procedures, technological advancements in fertility diagnostics, growing male reproductive health awareness, expansion of fertility treatment access in emerging markets. Major trends in the forecast period include rising adoption of assisted reproductive technologies, increasing use of advanced sperm diagnostic tests, growing focus on hormonal and targeted drug therapies, expansion of microsurgical treatments for male infertility, increasing awareness and early diagnosis of male infertility.
The rising stress levels are expected to drive the growth of the male infertility market in the coming years. Stress refers to the intensity of emotional, physical, or mental strain experienced in response to challenging situations or pressures. Increasing stress is largely driven by escalating work demands, where relentless pressure and high expectations contribute to burnout, disrupt mental health, and impair work-life balance. Elevated stress can affect hormone regulation, reduce sperm quality, and impair sexual function, leading to male infertility. Chronic stress alters cortisol and testosterone levels, contributing to a growing number of infertility cases. For example, in May 2024, according to the American Psychiatric Association, a US-based professional organization of psychologists, 43% of adults in the US reported feeling more anxious in 2024, compared with 37% in 2023 and 32% in 2022, demonstrating a consistent rise in anxiety levels. Consequently, increasing stress levels are fueling the growth of the male infertility market.
Major companies in the male infertility market are focusing on strategic partnerships to expand access to advanced fertility treatments globally. Strategic partnerships are collaborations that combine the resources and expertise of multiple organizations to achieve shared goals, driving innovation, expanding market reach, and enhancing R&D efforts. For example, in June 2024, Ferring Pharmaceuticals, a Switzerland-based pharmaceutical company, partnered with Posterity Health, a US-based male fertility clinic, to launch a male fertility program on Ferring’s Fertility Out Loud platform. The initiative provides men with confidential online assessments and educational resources developed by reproductive urologists, helping them understand their fertility status and addressing the stigma surrounding male infertility, which contributes to up to 50% of infertility cases. The program aims to empower men to take early action, potentially improving the couple’s path to parenthood by addressing male fertility issues sooner and more conveniently through digital tools and telehealth.
In June 2024, CooperSurgical, a US-based fertility and women’s healthcare company, acquired ZyMōt Fertility for an undisclosed amount. The acquisition is intended to strengthen CooperSurgical’s assisted reproductive technology (ART) portfolio by adding a patented sperm separation device that enhances motile sperm selection and improves pregnancy outcomes. ZyMōt Fertility is a US-based company specializing in advanced sperm separation devices for male infertility.
Major companies operating in the male infertility market are Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., NYU Langone Hospitals, Sun Pharmaceutical Industries Ltd., Cipla Limited, Ferring Pharmaceuticals, Fortis Healthcare, Vitrolife, Max Healthcare, CinnaGen Co., Aytu BioScience Inc., Zydus Hospitals and Healthcare Research Private Limited, Apricus Biosciences Inc., SCSA Diagnostics Inc., Andrology Solutions, Halotech DNA, Indira IVF, Conduit Pharmaceuticals, Shree IVF Clinics.
North America was the largest region in the male infertility market in 2025. The regions covered in the male infertility market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the male infertility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the male infertility market by increasing costs of imported fertility drugs, diagnostic equipment, and assisted reproductive technology consumables. These effects are most pronounced in art procedures and advanced sperm testing segments, particularly across North America, Europe, and Asia-Pacific regions. Higher tariffs have contributed to increased treatment costs in fertility centers and hospitals. However, tariffs have also encouraged domestic manufacturing of fertility diagnostics and localization of reproductive healthcare services.
The male infertility market research report is one of a series of new reports that provides male infertility market statistics, including male infertility industry global market size, regional shares, competitors with a male infertility market share, detailed male infertility market segments, market trends and opportunities, and any further data you may need to thrive in the male infertility industry. This male infertility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Male infertility is defined as a man’s inability to achieve pregnancy with a fertile female partner after one year of regular, unprotected sexual intercourse. It is generally caused by issues with sperm quantity or quality and may result from structural abnormalities, hormonal imbalances, genetic conditions, or other health factors.
The primary treatment types for male infertility include medication, surgery, and assisted reproductive technologies. Medications for male infertility aim to correct hormonal imbalances or stimulate sperm production, while avoiding synthetic testosterone due to its sperm-suppressing effects. Diagnosis involves tests such as sperm agglutination, DNA fragmentation analysis, oxidative stress evaluation, computer-assisted semen analysis, sperm penetration assays, and others. Treatments are distributed through hospital pharmacies, retail pharmacies, and online channels, and are used by hospitals, clinics, fertility centers, research institutes, and other end-users.
The male infertility market consists of revenues earned by entities by providing services such as diagnostic testing, counseling and lifestyle guidance, and hormonal therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The male infertility market includes sales of fertility supplements, semen analysis kits, surgical devices, and lifestyle and sperm health devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The male infertility market size is expected to see strong growth in the next few years. It will grow to $5.76 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to rising infertility rates due to environmental factors, increasing demand for ivf and icsi procedures, technological advancements in fertility diagnostics, growing male reproductive health awareness, expansion of fertility treatment access in emerging markets. Major trends in the forecast period include rising adoption of assisted reproductive technologies, increasing use of advanced sperm diagnostic tests, growing focus on hormonal and targeted drug therapies, expansion of microsurgical treatments for male infertility, increasing awareness and early diagnosis of male infertility.
The rising stress levels are expected to drive the growth of the male infertility market in the coming years. Stress refers to the intensity of emotional, physical, or mental strain experienced in response to challenging situations or pressures. Increasing stress is largely driven by escalating work demands, where relentless pressure and high expectations contribute to burnout, disrupt mental health, and impair work-life balance. Elevated stress can affect hormone regulation, reduce sperm quality, and impair sexual function, leading to male infertility. Chronic stress alters cortisol and testosterone levels, contributing to a growing number of infertility cases. For example, in May 2024, according to the American Psychiatric Association, a US-based professional organization of psychologists, 43% of adults in the US reported feeling more anxious in 2024, compared with 37% in 2023 and 32% in 2022, demonstrating a consistent rise in anxiety levels. Consequently, increasing stress levels are fueling the growth of the male infertility market.
Major companies in the male infertility market are focusing on strategic partnerships to expand access to advanced fertility treatments globally. Strategic partnerships are collaborations that combine the resources and expertise of multiple organizations to achieve shared goals, driving innovation, expanding market reach, and enhancing R&D efforts. For example, in June 2024, Ferring Pharmaceuticals, a Switzerland-based pharmaceutical company, partnered with Posterity Health, a US-based male fertility clinic, to launch a male fertility program on Ferring’s Fertility Out Loud platform. The initiative provides men with confidential online assessments and educational resources developed by reproductive urologists, helping them understand their fertility status and addressing the stigma surrounding male infertility, which contributes to up to 50% of infertility cases. The program aims to empower men to take early action, potentially improving the couple’s path to parenthood by addressing male fertility issues sooner and more conveniently through digital tools and telehealth.
In June 2024, CooperSurgical, a US-based fertility and women’s healthcare company, acquired ZyMōt Fertility for an undisclosed amount. The acquisition is intended to strengthen CooperSurgical’s assisted reproductive technology (ART) portfolio by adding a patented sperm separation device that enhances motile sperm selection and improves pregnancy outcomes. ZyMōt Fertility is a US-based company specializing in advanced sperm separation devices for male infertility.
Major companies operating in the male infertility market are Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., NYU Langone Hospitals, Sun Pharmaceutical Industries Ltd., Cipla Limited, Ferring Pharmaceuticals, Fortis Healthcare, Vitrolife, Max Healthcare, CinnaGen Co., Aytu BioScience Inc., Zydus Hospitals and Healthcare Research Private Limited, Apricus Biosciences Inc., SCSA Diagnostics Inc., Andrology Solutions, Halotech DNA, Indira IVF, Conduit Pharmaceuticals, Shree IVF Clinics.
North America was the largest region in the male infertility market in 2025. The regions covered in the male infertility market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the male infertility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the male infertility market by increasing costs of imported fertility drugs, diagnostic equipment, and assisted reproductive technology consumables. These effects are most pronounced in art procedures and advanced sperm testing segments, particularly across North America, Europe, and Asia-Pacific regions. Higher tariffs have contributed to increased treatment costs in fertility centers and hospitals. However, tariffs have also encouraged domestic manufacturing of fertility diagnostics and localization of reproductive healthcare services.
The male infertility market research report is one of a series of new reports that provides male infertility market statistics, including male infertility industry global market size, regional shares, competitors with a male infertility market share, detailed male infertility market segments, market trends and opportunities, and any further data you may need to thrive in the male infertility industry. This male infertility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Male infertility is defined as a man’s inability to achieve pregnancy with a fertile female partner after one year of regular, unprotected sexual intercourse. It is generally caused by issues with sperm quantity or quality and may result from structural abnormalities, hormonal imbalances, genetic conditions, or other health factors.
The primary treatment types for male infertility include medication, surgery, and assisted reproductive technologies. Medications for male infertility aim to correct hormonal imbalances or stimulate sperm production, while avoiding synthetic testosterone due to its sperm-suppressing effects. Diagnosis involves tests such as sperm agglutination, DNA fragmentation analysis, oxidative stress evaluation, computer-assisted semen analysis, sperm penetration assays, and others. Treatments are distributed through hospital pharmacies, retail pharmacies, and online channels, and are used by hospitals, clinics, fertility centers, research institutes, and other end-users.
The male infertility market consists of revenues earned by entities by providing services such as diagnostic testing, counseling and lifestyle guidance, and hormonal therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The male infertility market includes sales of fertility supplements, semen analysis kits, surgical devices, and lifestyle and sperm health devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Male Infertility Market Characteristics
3. Male Infertility Market Supply Chain Analysis
4. Global Male Infertility Market Trends and Strategies
5. Male Infertility Market Analysis of End Use Industries
7. Global Male Infertility Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Male Infertility Total Addressable Market (TAM) Analysis for the Market
9. Male Infertility Market Segmentation
10. Male Infertility Market Regional and Country Analysis
11. Asia-Pacific Male Infertility Market
12. China Male Infertility Market
13. India Male Infertility Market
14. Japan Male Infertility Market
15. Australia Male Infertility Market
16. Indonesia Male Infertility Market
17. South Korea Male Infertility Market
18. Taiwan Male Infertility Market
19. South East Asia Male Infertility Market
20. Western Europe Male Infertility Market
21. UK Male Infertility Market
22. Germany Male Infertility Market
23. France Male Infertility Market
24. Italy Male Infertility Market
25. Spain Male Infertility Market
26. Eastern Europe Male Infertility Market
27. Russia Male Infertility Market
28. North America Male Infertility Market
29. USA Male Infertility Market
30. Canada Male Infertility Market
31. South America Male Infertility Market
32. Brazil Male Infertility Market
33. Middle East Male Infertility Market
34. Africa Male Infertility Market
36. Male Infertility Market Competitive Landscape and Company Profiles
37. Male Infertility Market Other Major and Innovative Companies
40. Male Infertility Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Male Infertility Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses male infertility market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for male infertility? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The male infertility market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Treatment Type: Medication; Surgery; Assisted Reproductive Technology2) By Test Type: Sperm Agglutination; Deoxyribonucleic Acid Fragmentation Technique; Oxidative Stress Analysis; Computer Assisted Semen Analysis; Sperm Penetration Assay; Other Test Types
3) By Distribution Channel: Hospitals Pharmacies; Pharmacies And Drug Stores; Online Pharmacies
4) By End-User: Hospitals And Clinics; Fertility Centers; Research Institutes; Other End-Users
Subsegments:
1) By Medication: Hormone Treatments; Gonadotropins; Antibiotics; Antiestrogens; Dopamine Agonists2) By Surgery: Varicocelectomy; Vasovasostomy; Epididymovasostomy; Transurethral Resection of the Ejaculatory Duct (TURED); Sperm Retrieval Procedures
3) By Assisted Reproductive Technology (ART): In Vitro Fertilization (IVF); Intracytoplasmic Sperm Injection (ICSI); Intrauterine Insemination (IUI); Sperm Donation; Cryopreservation Of Sperm
Companies Mentioned: Novartis AG; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Intas Pharmaceuticals Ltd.; NYU Langone Hospitals; Sun Pharmaceutical Industries Ltd.; Cipla Limited; Ferring Pharmaceuticals; Fortis Healthcare; Vitrolife; Max Healthcare; CinnaGen Co.; Aytu BioScience Inc.; Zydus Hospitals and Healthcare Research Private Limited; Apricus Biosciences Inc.; SCSA Diagnostics Inc.; Andrology Solutions; Halotech DNA; Indira IVF; Conduit Pharmaceuticals; Shree IVF Clinics
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Male Infertility market report include:- Novartis AG
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- NYU Langone Hospitals
- Sun Pharmaceutical Industries Ltd.
- Cipla Limited
- Ferring Pharmaceuticals
- Fortis Healthcare
- Vitrolife
- Max Healthcare
- CinnaGen Co.
- Aytu BioScience Inc.
- Zydus Hospitals and Healthcare Research Private Limited
- Apricus Biosciences Inc.
- SCSA Diagnostics Inc.
- Andrology Solutions
- Halotech DNA
- Indira IVF
- Conduit Pharmaceuticals
- Shree IVF Clinics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 4.57 Billion |
| Forecasted Market Value ( USD | $ 5.76 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
